Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Breast Cancer Clinical Trials in New York | 329 Studies

Clinical Trials Breast CancerNew York

Breast Cancer Clinical Trials in New York

Find 329 clinical trials for breast cancer near New York, New York. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in New York

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 201-220 of 329 trials

UnknownA Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerThe primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of…NCT00486668·Mobile, Alabama and 109 others

Breast Cancer Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

SuspendedEribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast CancerThis randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that…NCT02037529·Scottsdale, Arizona and 38 others

Active not recruitingGedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of…NCT05501886·Birmingham, Alabama and 234 others

TerminatedPhase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerPrimary Objectives: Dose Escalation: * To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended…NCT03284957·Aurora, Colorado and 24 others

CompletedRandomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or MetastaticThe purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared…NCT00696072·Sedona, Arizona and 26 others

CompletedTriptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerRATIONALE: Estrogen can stimulate the growth of breast cancer cells.NCT00066703·Burbank, California and 227 others

CompletedInterleukin-12 in Treating Patients With Metastatic or Recurrent Breast CancerRATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill breast cancer cells.NCT00004893·Birmingham, Alabama and 48 others

CompletedPhase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast CancerFB-7 is a Phase II, multi-center randomized study of neratinib in combination with weekly paclitaxel with or without trastuzumab followed by doxorubicin and cyclophosphamide (AC)…NCT01008150·Loma Linda, California and 41 others

CompletedStudy of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerThe primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in…NCT01631552·Aurora, Colorado and 11 others

CompletedStudy of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerThe purpose of the study was to evaluate the safety and efficacy of a reduced ribociclib starting dose of 400 mg in combination with a non-steroidal aromatase inhibitor (NSAI)…NCT03822468·Mobile, Alabama and 88 others

Active not recruitingAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibThe purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an…NCT02955940·Santa Monica, California and 8 others

Active not recruitingBreast Cancer Index (BCI) RegistryThe purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical…NCT04875351·Daphne, Alabama and 104 others

RecruitingAxillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant ChemotherapyThe aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle…NCT04109079·Dublin and 97 others

Active not recruitingTamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerThis randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby…NCT02311933·Mobile, Alabama and 558 others

CompletedA Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerThis was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal…NCT00509769·Little Rock, Arkansas and 39 others

CompletedA Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast CancerThis study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether…NCT01101438·Anchorage, Alaska and 343 others

CompletedA Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsIn this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies.NCT02983045·La Jolla, California and 57 others

Active not recruitingAnastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastThis is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive…NCT03304080·New York, New York and 4 others

TerminatedTesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCCONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2 negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not…NCT03858972·Whittier, California and 24 others

CompletedOctreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00002967·Birmingham, Alabama and 107 others

PreviousPage 11 of 17Next

Other Conditions in New York

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma